Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study

We assessed the efficacy and safety of rituximab and its biosimilar, CT-P10, in treatment-na ïve low-tumor-burden follicular lymphoma patients, with a median follow-up of 29.2 months. Data from the trial show that the efficacy and safety of rituximab and CT-P10 were similar, including after a single switch from rituximab to CT-P10. These data support the therapeutic similarity of rituximab and CT-P10.

Source: Clinical Lymphoma, Myeloma and Leukemia - August 27, 2021 Category: Hematology Authors: Larry W. Kwak, Juan-Manuel Sancho, Seok-Goo Cho, Hideyuki Nakazawa, Junji Suzumiya, Gayane Tumyan, Jin Seok Kim, Tobias Menne, Jos é Mariz, Nikolai Ilyin, Wojciech Jurczak, Aurelio Lopez Martinez, Olga Samoilova, Edvard Zhavrid, Eduardo Yañez Ruiz, Mare Tags: Original article Source Type: research